Thymalin: Evidence, Mechanism, Dosing & Legal Status

Thymalin is a standardized low-molecular-weight polypeptide complex extracted from calf thymus, developed in the 1970s and 80s by Vladimir Khavinson's group and registered as an immunomodulatory drug in Russia and the CIS — the founding compound of the "Khavinson bioregulator" tradition.41 It is widely discussed in longevity and immune-optimization circles; what separates it from peptides like BPC-157 is that genuine human data exist. This monograph separates that human signal from the preclinical mechanism and the marketing.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Thymalin is not an FDA-approved drug in the United States; it is sold only as a "research chemical, not for human use," and should be treated as prohibited in sport. Doses are reported strictly as they appear in the published literature and Russian clinical use, for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Thymalin and how does it work?

Thymalin is not a single defined peptide. It is a sterile, lyophilized standardized acid-extract of bovine (calf) thymus tissue, ultrafiltered to a low-molecular-weight fraction of roughly 1 to 10 kDa, containing a mixture of regulatory polypeptides.47 From this complex, Khavinson's group isolated by reversed-phase HPLC the active dipeptide L-Glu-L-Trp (EW), which was synthesized and marketed separately as Thymogen — so Thymalin (the complex) and Thymogen (the purified dipeptide) are related but distinct products. Some consumer peptide sites incorrectly describe Thymalin itself as the dipeptide Glu-Trp; the primary literature is clear that Thymalin is the polypeptide complex.4 The immunoactive fragments characterized within or derived from the complex are the dipeptides EW (Glu-Trp, thymogen) and KE (Lys-Glu, vilon) and the tripeptide EDP (crystagen).1

The proposed mechanism is epigenetic. Khavinson's central hypothesis is that these ultra-short peptides penetrate the cell and nuclear membranes and bind site-specifically to double-stranded DNA and histone proteins, modulating gene expression — for example, KE selectively binding the TCGA sequence and EW the GGAG sequence, with molecular modeling showing preferential binding to histones H1/3, H2b, H3 and H4.15 Downstream, the peptides are reported to regulate heat-shock proteins, multiple cytokines and "gerontogenes," and to influence hematopoietic and stem-cell differentiation.1 The clinical rationale is reversal of thymic involution: thymic output of naive T-cells falls sharply after puberty, and Thymalin is proposed to partially restore T-cell maturation, NK activity and the CD4/CD8 ratio in the aged.1 This molecular model is graded C-to-D: it rests on modeling and in-vitro work from a single lineage and has not been confirmed by independent structural biology. As an injected peptide mixture, oral bioavailability is negligible, so clinical use is intramuscular; secondary references cite a plasma half-life on the order of about 30 minutes for the active short peptides.15

What is the evidence by indication?

Thymalin's evidence is unusual among longevity peptides in that human, not merely animal, data exist — but it is concentrated in older adults and almost entirely single-lineage. The table below grades each indication.

The best-evidenced use is immune restoration in the elderly. Decades of Russian clinical use report that short Thymalin courses normalize lymphocyte counts, NK-cell activity, CD4 counts and the CD4/CD8 ratio toward younger patterns, and reduce acute respiratory disease incidence by 2.0 to 2.4-fold in elderly and senile patients.12 Human controlled-cohort evidence exists, but it is single-lineage, often open-label, and unreplicated — hence B rather than A.

For severe COVID-19 the data rise to RCT level. A small randomized, placebo-controlled trial randomized severe-COVID-19 patients to Thymalin 10 mg in 2 mL 0.9% NaCl intramuscularly daily for 10 days plus standard of care versus placebo plus standard of care; the companion publication reported faster clinical improvement, higher recovery from lymphopenia, faster normalization of CRP and D-dimer, and roughly halved in-hospital mortality in older patients.35 A separate analysis reported Thymalin slowed the decline of anti-SARS-CoV-2 IgG.6 The trials are small, single-region (Transbaikal/Chita), and unreplicated outside Russia; the authors' claim of efficacy "superior to tocilizumab" was not derived from a head-to-head trial. You can read the randomized-trial abstract directly at the European Respiratory Journal.

The landmark longevity study followed 266 elderly people over six to eight years, dosing bioregulators in the first two to three years, and reported all-cause mortality reductions versus controls of about 2.0 to 2.1-fold for Thymalin alone and up to 4.1-fold for combined annual Thymalin plus Epithalamin over six consecutive years.2 Although MEDLINE tags it as a randomized controlled trial, independent analysts note it was not blinded, randomization methodology is unclear, and controls were drawn from the same background population, allowing selection effects of arbitrary size — and no independent group has reproduced it.14

What doses appear in the literature?

Reported strictly as information, not a protocol or recommendation; Thymalin is not FDA-approved. The route used in the published trials and Russian product labeling is intramuscular injection.3 The dose and course as studied is 10 mg once daily intramuscularly for 10 days, roughly 100 mg per course, in both the COVID-19 trial and the geroprotection program; the elderly longevity work used annual repeat courses over multiple years.32 Lower maintenance regimens — for example 5 mg/day for 5 to 10 days, repeated every 3 to 6 months — appear in non-clinical community sources and should be read as anecdotal practice, not trial-derived.15 The product is supplied as a sterile lyophilized powder, commonly 10 mg per vial, reconstituted in 1 to 2 mL of 0.9% sodium chloride; the COVID trial used 10 mg in 2 mL.15

How safe is Thymalin?

The primary Russian literature characterizes Thymalin and Thymogen as having "practically no side effects," and the COVID-19 and elderly studies did not report significant treatment-related harms.41 From a functional, root-cause standpoint that framing is itself a limitation: it reflects decades-old, non-standardized adverse-event capture rather than rigorous modern pharmacovigilance, so the apparently clean profile is low-confidence. The most plausible real-world risks are local injection-site reactions and, because the product is a bovine-tissue extract, hypersensitivity to foreign protein; the historically discussed risk of transmissible agents from animal-tissue sourcing argues for pharmaceutical-grade supply only.7 Because the proposed mechanism includes broad gene-expression modulation and stem-cell differentiation, theoretical off-target proliferative or immune effects cannot be excluded and have not been formally studied long-term in humans.1 Pregnancy and lactation have no safety data and should be considered contraindicated, and pediatric data are absent. A distinct hazard is supply itself: product sold in the U.S. as a research chemical carries no guarantee of identity, purity, sterility or endotoxin control.10

What is the FDA and WADA status in 2026?

Thymalin is not FDA-approved for any indication and has no recognized U.S. compounding pathway.9 It should not be conflated with thymosin alpha-1, a different, better-characterized thymic peptide that was placed on the FDA 503A interim Category 2 list in 2023 and then went through nominator withdrawal and PCAC review; in 2026, HHS/FDA action moved a set of peptides out of Category 2, with a PCAC meeting scheduled July 23-24, 2026 to consider several peptides for the 503A bulks list.1011 Thymalin, the calf-thymus complex, is not among those reviewed compounding substances and remains outside the U.S. drug and compounding framework — sold domestically, when sold, only as a research chemical not for human use. It is not a DEA-scheduled controlled substance. In Russia and the CIS it has been registered and clinically used as an immunomodulatory pharmaceutical for over 40 years.4

For athletes the picture demands caution. Thymalin is not listed by name on the WADA 2026 Prohibited List, in force since 1 January 2026, but a non-approved-for-human-use immunomodulatory peptide most reasonably falls under category S0, non-approved substances, prohibited at all times.12 Tested athletes should treat it as prohibited. Note that the thymosin-beta-4 fragment TB-500 is a different peptide and is explicitly prohibited, with multi-year sanctions imposed for its use — do not generalize that explicit ban to Thymalin, but do not assume Thymalin is permitted either.13

Bottom line. Thymalin is the most clinically studied Khavinson bioregulator and genuinely has human trial data — graded B for immune restoration in the elderly and adjunctive benefit in severe COVID-19. The headline geroprotective mortality reductions are so large that, absent independent replication, they must be read as hypothesis-generating rather than established, and broad anti-aging use in healthy younger adults is unproven (Grade D). The dominant uncertainty is source-quality: essentially the entire evidence base comes from a single Russian research lineage, with small samples, weak blinding, and zero independent Western replication in over 40 years. Combined with its non-FDA-approved, research-chemical-only U.S. status and the safety risks of unregulated bovine-extract supply, Thymalin is best characterized as a biologically interesting, human-studied, but unverified immune bioregulator — not a validated therapy. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.